Elutia Inc. (NASDAQ:ELUT) Sees Large Increase in Short Interest

Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 30th, there was short interest totaling 33,661 shares, an increase of 119.6% from the October 15th total of 15,326 shares. Based on an average daily volume of 70,790 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings cut Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, Elutia currently has a consensus rating of “Sell”.

View Our Latest Research Report on Elutia

Elutia Stock Performance

ELUT traded up $0.01 during midday trading on Monday, hitting $0.83. 39,841 shares of the company were exchanged, compared to its average volume of 161,569. The firm has a market capitalization of $36.85 million, a price-to-earnings ratio of 0.75 and a beta of 0.93. The company has a current ratio of 2.63, a quick ratio of 2.61 and a debt-to-equity ratio of 0.53. The company’s 50 day simple moving average is $0.82 and its 200 day simple moving average is $0.97. Elutia has a 1-year low of $0.50 and a 1-year high of $1.39.

Elutia (NASDAQ:ELUT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. Elutia had a negative return on equity of 140.53% and a net margin of 546.70%. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.00 million.

Elutia Company Profile

(Get Free Report)

Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.

Featured Stories

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.